Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)
ID: 351096Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351096

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-017.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Miniaturization and Automation of Tissue Chip Systems (MATChS)" through the Small Business Innovation Research (SBIR) cooperative agreement mechanism. This initiative aims to support the development of automated, miniaturized tissue chip platforms that enhance microphysiological systems (MPS) for improved drug discovery and regulatory assessments, with a focus on creating portable systems that maintain 3D tissue constructs and integrate real-time monitoring technologies. The program is significant in advancing innovative in vitro methods that can potentially replace traditional animal testing in biomedical research, aligning with current regulatory trends favoring alternative assessment methods. Interested small businesses can apply for a total funding commitment of up to $2.15 million, with applications due by January 22, 2024, and the earliest project start date anticipated for February 22, 2024. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-TR-23-017-Full-Announcement.html
    RFA-TR-23-017.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Center for Advancing Translational Sciences (NCATS), announces the Miniaturization and Automation of Tissue Chip Systems (MATChS) funding opportunity. This initiative aims to enhance microphysiological systems (MPS) by developing automated, miniaturized tissue chip platforms to improve drug discovery and regulatory assessments. Funding through the Small Business Innovation Research (SBIR) cooperative agreements (U43/U44) supports projects that create portable systems to maintain 3D tissue constructs and integrate real-time monitoring technologies. Key details include a commitment of up to $2.15 million to fund two Phase I projects and one Phase II project. Applications are due by January 22, 2024, and the earliest start date is February 22, 2024. The opportunity seeks to facilitate collaboration between small business concerns and NIH, ensuring milestone-driven progress and commercialization pathways. Applicants must adhere to specific requirements outlined in the application guide, ensuring compliance with NIH standards. This program represents a significant push towards innovative in vitro methods that can replace traditional animal testing in biomedical research, aligning with current regulatory trends favoring alternative assessment methods.
    Similar Opportunities
    Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Miniaturization and Automation of Tissue Chip Systems (MATChS)" aimed at supporting Small Business Technology Transfer (STTR) applications. This initiative seeks to enhance microphysiological systems that replicate organ functions, focusing on the development of compact, automated systems for real-time analysis of tissue health to improve drug discovery and precision medicine. Eligible U.S.-based small businesses can apply for funding of up to $2.15 million for Phase I and Phase II awards, with proposals required to demonstrate innovation, a clear commercialization strategy, and collaboration with NIH staff. Interested applicants should refer to the full announcement available at NIH Grants and note that the application deadline is February 23, 2026.
    PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), has announced the PHS 2024-2 Omnibus Solicitation for Small Business Innovation Research (SBIR) Grant Applications. This funding opportunity invites eligible U.S. small businesses to submit applications for Phase I, Phase II, Fast-Track, and Direct to Phase II projects that align with the research missions of the NIH, CDC, and FDA, with a focus on stimulating technological innovation and commercialization of federal R&D investments. Notably, applications must not include clinical trials, and funding levels are capped at $306,872 for Phase I and up to $2,045,816 for Phase II, with a submission deadline of April 5, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) to develop extracellular vesicle (EV)-based therapeutic platforms aimed at regenerative medicine. The primary objective of this funding opportunity announcement (FOA) is to support the production and manufacturing of both native and engineered EVs for tissue and organ repair, with applications focusing on feasibility and initial proof of concept in Phase I, and optimization and scaling in Phase II. This initiative is crucial for advancing regenerative medicine technologies and addressing challenges in EV therapeutics, ultimately facilitating their application in clinical settings. Eligible applicants can receive funding up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by June 6, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-268.html.
    Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small businesses to develop novel extracellular vesicle (EV)-based therapeutic platforms aimed at regenerative medicine through a cooperative agreement. The primary objective is to support the production, manufacturing, and application of EVs for tissue and organ repair, with a focus on utilizing stem cells for EV generation and ensuring GMP-compliant production. This initiative is critical for advancing therapeutic technologies in regenerative medicine, with funding amounts capped at $295,924 for Phase I and $1,972,828 for Phase II grants, while clinical trials are not permitted under this opportunity. Interested applicants must adhere to strict submission guidelines and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, with the application deadline set for June 6, 2025.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 grant mechanism to support the development of next-generation human cell-derived microphysiological systems (MPS) that accurately replicate the architectures and functions of the human nervous system. This initiative aims to encourage high-risk, high-reward exploratory research, particularly relevant for addressing complex nervous system disorders, and is open to a diverse range of eligible applicants, including educational institutions, non-profits, and governmental entities. The funding, capped at $275,000 over a two-year period, emphasizes collaboration among experts in neurobiology, engineering, and ethics, and applications must adhere to NIH data management and sharing policies. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with the application deadline set for January 7, 2026.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) aimed at advancing research in the development of next-generation human cell-derived microphysiological systems (MPS) that accurately replicate complex nervous system physiology. This funding opportunity, under the R01 Research Project Grant mechanism, encourages innovative applications that focus on enhancing existing technologies and creating sophisticated models for studying the nervous system's development, function, and aging, while explicitly excluding clinical trial projects. Eligible applicants include a diverse range of organizations, such as educational institutions and community-based organizations, with no specific budget limits as long as costs align with the proposed research. Interested parties should note that the application submission period opens on January 3, 2025, with a closing date of January 7, 2026, and are encouraged to contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NeuroNEXT Small Business Innovation in Clinical Trials," aimed at encouraging small businesses to conduct exploratory clinical trials of investigational agents related to neurological disorders. This initiative seeks applications for Phase II Small Business Innovation Research (SBIR) projects, with a budget of up to $3 million over five years, focusing on trials that align with the strategic plan of the National Institute of Neurological Disorders and Stroke (NINDS). The program is designed to foster public-private partnerships to enhance the development and commercialization of innovative therapies, ultimately improving clinical outcomes in neuroscience research. Interested applicants must adhere to a Community Engagement and Research Inclusion (CERI) plan, with the first application deadline set for January 5, 2025, and additional deadlines throughout 2026 and 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the PHS 2024-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) Grant Applications, inviting eligible U.S. small businesses to submit proposals for innovative projects that align with NIH's research and development mission. This funding opportunity, identified as PA-24-247, specifically excludes clinical trials and aims to foster collaboration between small businesses and research institutions to advance technology development in health-related fields. Eligible applicants must be for-profit small businesses based in the U.S., with budget limits set at $306,872 for Phase I and $2,045,816 for Phase II awards. The application deadline is April 5, 2025, with an initial submission date of September 5, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)," aimed at advancing research in human cell-derived microphysiological systems (MPS) that replicate complex nervous system architectures and functions. This initiative seeks innovative applications that address technological barriers in studying nervous system development and diseases, with a focus on improving physiological relevance and circuit-level activity in existing assays. The funding is open to a wide range of eligible applicants, including higher education institutions and non-profits, with a project period of up to five years and no cost-sharing requirement. Interested parties should note that the application deadline is January 7, 2026, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the announcement page at https://grants.nih.gov/grants/guide/pa-files/PAR-23-046.html.